CBD oil: Your patients are using it. Here's what you need to know.
Journal
JAAPA : official journal of the American Academy of Physician Assistants
ISSN: 1547-1896
Titre abrégé: JAAPA
Pays: United States
ID NLM: 9513102
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
medline:
6
9
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
Cannabinoid (CBD) oil is a trend in self-care management. In this digital age, patients have access to products from across the globe, and these products may not be regulated. Healthcare providers must be at the forefront of the latest trends in medicine and alternative therapies to better serve patients' needs. This article reviews various medical conditions for which CBD oil already is being used, its other medicinal uses, major adverse reactions, and what patients should know before they decide to consume CBD oil.
Identifiants
pubmed: 37668478
doi: 10.1097/01.JAA.0000944604.27500.5d
pii: 01720610-202309000-00008
doi:
Types de publication
Review
Journal Article
Langues
eng
Pagination
29-33Informations de copyright
Copyright © 2023 American Academy of Physician Associates.
Références
Kis B, Ifrim FC, Buda V, et al. Cannabidiol—from plant to human body: a promising bioactive molecule with multi-target effects in cancer. Int J Mol Sci. 2019;20(23):5905.
Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018;3(1):152–161.
Gill L. CBD goes mainstream. www.consumerreports.org/cbd/cbd-goes-mainstream. Accessed April 28, 2023.
Alsherbiny MA, Li CG. Medicinal cannabis—potential drug interactions. Medicines. 2018;6(1):3.
Borchardt D. Survey: nearly half of people who use cannabidiol products stop taking traditional medicines. www.forbes.com/sites/debraborchardt/2017/08/02/people-who-use-cannabis-cbd-products-stop-taking-traditional-medicines/#765362182817. Accessed April 5, 2023.
Market Data Forecast. Global cannabidiol market size, share, trends, COVID-19 impact & growth forecast report—segmented by type (hemp and marijuana), distribution channel, end-user & region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa)—industry analysis from 2023 to 2028. www.marketdataforecast.com/market-reports/CBD-oil-market. Accessed April 28, 2023.
National Cancer Institute. Cannabis and Cannabinoids (PDQ)–Health Professional Version. www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq. Accessed April 5, 2023.
US Food and Drug Administration. What you need to know (and what we're trying to find out) about products containing cannabis and cannabis-derived compounds, including CBD. www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis. Accessed April 5, 2023.
VanDolah HJ, Bauer BA, Mauck KF. Clinicians' guide to cannabidiol and hemp oils. Mayo Clin Proc. 2019;94(9):1840–1851.
US Food and Drug Administration. Hemp production and the 2018 farm bill. www.fda.gov/news-events/congressional-testimony/hemp-production-and-2018-farm-bill-07252019. Accessed April 5, 2023.
Raypole C. A simple guide to the endocannabinoid system. www.healthline.com/health/endocannabinoid-system. Accessed April 5, 2023.
Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138–141.
Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1):bjgpopen20X101010.
Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016;1(1):154–165.
Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2015;20(6):936–948.
Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4:245–259.
Agarwal R, Burke SL, Maddux M. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders. BMC Psychiatry. 2019;19(1).
Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol. 2019;10:2466.
Centers for Disease Control and Prevention. Data and statistics on autism spectrum disorder. www.cdc.gov/ncbddd/autism/data.html. Accessed April 28, 2023.
Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226.
Sarris J, Sinclair J, Karamacoska D, et al. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020;20(1).
Shannon S, Opila-Lehman J. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med (Encinitas). 2015;14(6):31–35.
Pavlovic R, Nenna G, Calvi L, et al. Quality traits of “cannabidiol oils”: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules. 2018;23(5):1230.
Steele W. How to find high-quality CBD oil. www.greenmarketreport.com/how-to-find-high-quality-cbd-oil. Accessed April 5, 2023.
Chesak J. How CBD interacts with medications. www.healthline.com/health/cbd-and-drug-interactions-what-you-need-to-know. Accessed April 5, 2023.
Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8(7):989.